Home > News > Headline News > Archive

Click on title to read the full article.

MD Anderson initiates Phase 1/2 entinostat-lapatinib ditosylate combination study in metastatic breast cancer

April 13, 2012

Syndax Pharmaceuticals, Inc., a clinical-stage epigenetics oncology company, announced that investigators at The University of Texas MD Anderson Cancer Center Department of Breast Medical Oncology have initiated a phase 1/2 study combining Syndax's lead product entinostat with lapatinib ditosylate (Tykerb) in patients with locally recurrent or distant relapsed metastatic breast cancer previously treated with trastuzumab (Herceptin®).

Rare Circulating Tumor Cells, Elusive Double Positive Cells May Be Overlooked by Current Blood Analysis Techniques

April 13, 2012

New research from The Ohio State University utilizes two different methods to visualize circulating tumor cells (CTCs) as well as other unusual circulating cells with both epithelial and hematopoietic characteristics in metastatic breast cancer.

Roche's Trastuzumab Emtansine Has Positive Results Against Metastatic Breast Cancer

April 4, 2012

By Rupert Shepherd

Overall survival rates are not ready for release yet, but it appears that Trastuzumab Emtansine controlled the metastatic cancer better than standard treatments.

1st International consensus guidelines for advanced breast cancer (ABC 1)

April 3, 2012

By The Breast

The 1st international Consensus Conference for Advanced Breast Cancer (ABC 1) took place on November
2011, in Lisbon. Consensus guidelines for the management of this disease were developed. This manuscript
summarizes these international consensus guidelines

 < 1 2